• Molecular Partners dosed first patients in a US Phase 1/2a trial of MP0712, a DLL3-targeting 212Pb Radio-DARPin partnered with Orano Med.
• Cohort 1 recruitment completed; repeat dosing underway as the study evaluates safety across up to four dose levels.
• Program uses a matched diagnostic-therapeutic approach, starting with 203Pb imaging and dosimetry to predict tumor uptake before treatment.
• Initial data expected in 2026; broader safety and efficacy results targeted for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-004433), on July 02, 2026, and is solely responsible for the information contained therein.